Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;27(5):901-912.
doi: 10.1038/s41593-024-01609-3. Epub 2024 Mar 21.

Myeloid cell replacement is neuroprotective in chronic experimental autoimmune encephalomyelitis

Marius Marc-Daniel Mader  1   2 , Alan Napole #  1   2 , Danwei Wu #  1   2   3 , Micaiah Atkins  4 , Alexa Scavetti  1   2 , Yohei Shibuya  1   2 , Aulden Foltz  4 , Oliver Hahn  4 , Yongjin Yoo  1   2 , Ron Danziger  1   2 , Christina Tan  1   2 , Tony Wyss-Coray  4 , Lawrence Steinman  3 , Marius Wernig  5   6
Affiliations

Myeloid cell replacement is neuroprotective in chronic experimental autoimmune encephalomyelitis

Marius Marc-Daniel Mader et al. Nat Neurosci. 2024 May.

Abstract

Multiple sclerosis (MS) is an autoimmune disease characterized by demyelination of the central nervous system (CNS). Autologous hematopoietic cell transplantation (HCT) shows promising benefits for relapsing-remitting MS in open-label clinical studies, but the cellular mechanisms underlying its therapeutic effects remain unclear. Using single-nucleus RNA sequencing, we identify a reactive myeloid cell state in chronic experimental autoimmune encephalitis (EAE) associated with neuroprotection and immune suppression. HCT in EAE mice results in an increase of the neuroprotective myeloid state, improvement of neurological deficits, reduced number of demyelinated lesions, decreased number of effector T cells and amelioration of reactive astrogliosis. Enhancing myeloid cell incorporation after a modified HCT further improved these neuroprotective effects. These data suggest that myeloid cell manipulation or replacement may be an effective therapeutic strategy for chronic inflammatory conditions of the CNS.

PubMed Disclaimer

Update of

References

    1. Wallin, M. T. et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 269–285 (2019).
    1. Miller, A. E. et al. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the national multiple sclerosis society. JAMA Neurol. 78, 241–246 (2021). - PubMed
    1. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M. & Weinshenker, B. G. Multiple sclerosis. N. Engl. J. Med. 343, 938–952 (2000). - PubMed
    1. Yong, H. Y. F. & Yong, V. W. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat. Rev. Neurol. 18, 40–55 (2022). - PubMed
    1. Mancardi, G. L. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 84, 981–988 (2015). - PubMed

Publication types